Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m(2)/day x7 days (n = 240) or conventional care reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Döhner, Hartmut, Dolnik, Anna, Tang, Lin, Seymour, John F., Minden, Mark D., Stone, Richard M., del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Santini, Valeria, Vyas, Paresh, Beach, C. L., MacBeth, Kyle J., Skikne, Barry S., Songer, Steve, Tu, Nora, Bullinger, Lars, Dombret, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286388/
https://www.ncbi.nlm.nih.gov/pubmed/30275526
http://dx.doi.org/10.1038/s41375-018-0257-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286388/
https://www.ncbi.nlm.nih.gov/pubmed/30275526
http://dx.doi.org/10.1038/s41375-018-0257-z

Ejemplares similares